Findings, possible implications, and reported experiences.
About Testosterone
Small moleculeEndocrine & hormones
Primary research area
Endocrine · muscle & performance
Regulatory status
Prescription medicine
Evidence level
Human, indication-specific
Primary mechanism
Androgen-receptor agonist; converts partly to estradiol and DHT
Reference profile available · Coverage varies by section
Also known as Testosterone cypionate · Testosterone enanthate · Testosterone propionate · Testosterone undecanoate · Testosterone phenylpropionate · Testosterone isocaproate · Testosterone suspension · Sustanon · mixed testosterone esters · Sustanon / mixed testosterone esters · Sustanon 250 · Nebido · Aveed · Testosterone base / no ester
Testosterone is the principal endogenous androgen. Testosterone cypionate is an injectable ester that releases testosterone after intramuscular administration. [1]
What has been observed?
Selected source-linked reading notes, not the complete literature or a pooled conclusion.
Human · Abstract reviewed
What does the prostate analysis leave unresolved?
Topical gel versus placebo; 5,204 men analyzed.
High-grade prostate cancer occurred in 5 of 2,596 testosterone-treated men and 3 of 2,602 placebo-treated men. The difference was not statistically significant; PSA rose more with testosterone.
Limits & adverse findings: Participants at high prostate-cancer risk were excluded. Few events and limited follow-up constrain precision. This is a TRAVERSE analysis, sharing its registration with the cardiovascular report.
What did TRAVERSE establish about cardiovascular events?
1.62% gel targeting 350–750 ng/dL; mean treatment 21.7 months, follow-up 33 months.
The primary cardiovascular event occurred in 7.0% with testosterone and 7.3% with placebo. The trial met its prespecified noninferiority criterion.
Limits & adverse findings: 5,246 men aged 45–80 with low testosterone and existing or increased cardiovascular risk. Results do not establish safety at higher exposures or across all formulations. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.
The cited label covers replacement therapy in males with symptoms or conditions associated with deficiency or absence of endogenous testosterone, including primary and hypogonadotropic hypogonadism. [1]
Known half-life
About 8 days after intramuscular testosterone cypionate administration. This value is specific to the cypionate ester and route, not every testosterone preparation. [1]
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits
Replacement labeling does not establish an optimal muscle-gain exposure. The label says the product has not been shown safe and effective for athletic enhancement and describes risks including suppression of sperm production, polycythemia, edema and possible lipid changes. [1]
Safety & evidence boundaries
Source-specific information, not a personal safety clearance or monitoring plan.
Replacement labeling does not establish an optimal muscle-gain exposure. The label says the product has not been shown safe and effective for athletic enhancement and describes risks including suppression of sperm production, polycythemia, edema and possible lipid changes.
Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Candidate categories use titles and any reviewed intervention metadata. Treatment candidates can include reviews or protocols; this filter does not certify a treatment experiment.
Study model describes the source. Confidence depends on methods, replication, population and outcome.